FDA/EMA-approved CD19- and BCMA-specific CAR T cell products are mainly last line therapies, however, ironically provide high complete remission induction rates and increase overall survival in B-lineage cancers including multiple myeloma substantially (86). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.